# Role of CRISPR-Cas9 in Gene Editing: Clinical Trial Findings and Therapeutic Applications

**Avni Vishwas1 Shreosee Ghosh2 Rupak Roy2**

1RV PU College, Jayanagar

2SHRM Biotechnologies Pvt. Ltd., Madhyamgram, Kolkata, West Bengal, India

\*Corresponding Author’s Email Id: rupak@shrmbio.com

# Abstract

CRISPR-Cas9 has revolutionized gene editing by enabling precise, efficient, and cost-effective genome modifications. This paper highlights the most significant clinical trial findings that demonstrate the therapeutic potential of CRISPR-based treatments for genetic disorders such as Sickle Cell Disease (SCD), Cystic Fibrosis (CF), and Leber Congenital Amaurosis (LCA). Additionally, it explores CRISPR’s role in advancing CAR-T cell therapies for hematological malignancies. The paper emphasizes clinical outcomes, treatment efficacy, safety, and future potential for CRISPR in personalized medicine.

Keywords: CRISPR-Cas9, gene editing, clinical trials, sickle cell disease, cystic fibrosis, Leber congenital amaurosis, CAR-T cell therapy, genome modification, precision medicine.

# Introduction

Genetic disorders present significant treatment challenges, with many conditions lacking curative therapies. Traditional treatment approaches often focus on symptom management rather than addressing the underlying genetic cause. CRISPR-Cas9, a gene-editing technology derived from bacterial immune defense mechanisms, has introduced the possibility of directly correcting disease-causing mutations. This paper reviews clinical trials investigating CRISPR- based therapies, detailing their methodologies, findings, and potential for widespread medical application.

# Mechanism of CRISPR-Cas9 Gene Editing

CRISPR-Cas9 enables targeted genome modifications through:

* **Cas9 Nuclease**: Introduces double-strand DNA breaks at specific sites.
* **Guide RNA (gRNA)**: Directs Cas9 to the target sequence.
* **DNA Repair Mechanisms**: Cells repair breaks via Non-Homologous End Joining (NHEJ) (leading to gene disruption) or Homology-Directed Repair (HDR) (enabling precise gene correction).

These mechanisms provide a foundation for developing gene therapies targeting various genetic disorders.

**Figure:** Process of conducting clinical trials for CRISPR-based gene therapies

# CRISPR Therapy for Genetic Diseases: Clinical Trial Data and Findings Sickle Cell Disease (SCD)

SCD is an inherited disorder caused by a point mutation in the β-globin gene, leading to the production of abnormal hemoglobin S (HbS), red blood cell sickling, and vaso-occlusive complications. CRISPR-based therapies aim to mitigate disease pathology by reactivating fetal hemoglobin (HbF) expression, which can compensate for defective adult hemoglobin.

# CLIMB-SCD-121 Trial (Casgevy - Vertex/CRISPR Therapeutics)

In this Phase 1/2 trial, autologous hematopoietic stem cells were extracted from patients, genetically modified using CRISPR-Cas9 to disrupt the BCL11A gene (a repressor of HbF expression), and reinfused following myeloablative conditioning. 92% of patients remained free from vaso-occlusive crises 12 months post-treatment, demonstrating sustained therapeutic benefit. Increased HbF levels were observed in all participants, and no major off-target effects were reported.

# Lyfgenia Trial (Bluebird Bio)

Unlike Casgevy, Lyfgenia utilizes a lentiviral vector to introduce a functional beta-globin gene into patients’ hematopoietic stem cells, promoting the production of a functional hemoglobin variant. 80% of patients achieved transfusion independence within one year. Although mild conditioning-related adverse effects were reported, long-term safety profiles remain favourable.

# Cystic Fibrosis (CF)

CF is an autosomal recessive disorder caused by mutations in the CFTR gene, resulting in defective chloride ion transport and multi-organ dysfunction. CRISPR-based strategies aim to restore CFTR function either by correcting mutations or inserting a functional copy of the gene.

# Ex vivo CRISPR Gene-Edited CFTR Cells Trial

Patient-derived airway basal stem cells were genetically corrected using CRISPR-Cas9 and then expanded in vitro before being reintroduced into the respiratory epithelium. Chloride channel function was restored in 70% of lab-cultured cells. While animal models demonstrated improved mucus clearance and lung function, human trials are ongoing to assess long-term efficacy and durability.

# In vivo CRISPR-LNP Therapy Trial

This approach utilizes lipid nanoparticles (SORT LNPs) to deliver CRISPR-Cas9 components directly to lung epithelial cells via inhalation. Preclinical trials demonstrated a 40% improvement in lung function with sustained gene correction. Early-phase human trials suggest promising safety and potential therapeutic benefits.

# Leber Congenital Amaurosis (LCA)

LCA is a severe inherited retinal dystrophy primarily caused by CEP290 mutations. CRISPR- based gene therapy seeks to correct the IVS26 mutation to restore photoreceptor function.

# EDIT-101 Trial (Editas Medicine)

EDIT-101 is an AAV5-delivered CRISPR therapy designed to introduce precise deletions in the CEP290 gene to restore proper splicing. Patients received subretinal injections of the therapy. Over 60% of patients demonstrated measurable improvements in visual acuity. While some experienced mild inflammation, no severe adverse events were recorded.

# CRISPR-Edited CAR-T Cell Therapies for Cancer

CRISPR has enhanced CAR-T cell therapy by improving tumor targeting specificity, reducing immune rejection, and increasing persistence in circulation.

# COBALT™-LYM Trial (CTX130 - CRISPR Therapeutics)

This study evaluated allogeneic T-cells edited to target CD70, a protein highly expressed in T- cell lymphomas. CRISPR was used to remove endogenous T-cell receptors to minimize graft- versus-host disease. 70% of patients achieved an overall response, with 30% achieving complete remission. Compared to traditional CAR-T therapies, toxicity was lower, and immune rejection was minimized.

# ET-901 Trial (Allogene Therapeutics)

Patients with relapsed/refractory B-cell non-Hodgkin lymphoma received CRISPR-edited CD19-targeting T-cells engineered for enhanced persistence. 100% of patients demonstrated an objective response in Phase 1 trials, indicating significant therapeutic potential.

# ALLO-329 (Dual-Target CAR-T Therapy, Allogene Therapeutics)

This trial investigates a dual-targeting approach against both CD19 and CD70 for hematologic malignancies and autoimmune disorders. Early-stage data suggest enhanced tumor clearance with prolonged T-cell activity. Further trials are needed to assess long-term benefits.

# FDA-Approved CRISPR and CAR-T Therapies

Kymriah and Yescarta are the first FDA-approved CAR-T therapies demonstrating durable remissions in hematologic malignancies.

# Kymriah – Pediatric ALL

Achieved an 81% complete response rate in relapsed pediatric acute lymphoblastic leukemia patients.

# Yescarta – Mantle Cell Lymphoma

Demonstrated a 93% response rate in mantle cell lymphoma patients, with long-term follow- ups indicating sustained remission.

# Challenges and Future Directions

Despite promising results, CRISPR-based therapies face challenges:

* **Off-Target Effects**: Ongoing research aims to improve precision editing and reduce unintended mutations.
* **Regulatory and Ethical Considerations**: Issues surrounding human genome editing require stringent oversight.
* **Delivery Efficiency**: Novel vectors and delivery systems are under investigation to enhance in vivo applications.

Future research will focus on refining these therapies, broadening their applicability, and ensuring accessibility.

# Conclusion

CRISPR-Cas9 represents a paradigm shift in gene therapy, with extensive clinical data validating its efficacy in treating genetic disorders and advancing CAR-T therapies. The continued refinement of this technology will determine its long-term viability as a mainstream medical intervention.

# References

1. Frangoul, H., et al. (2021). "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β- Thalassemia." *New England Journal of Medicine*, 384(3), 252-260.
2. Schwank, G., et al. (2013). "Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids." *Cell Stem Cell*, 13(6), 653-658.
3. Alapati, D., et al. (2022). "Lipid Nanoparticle Delivery of CRISPR-Cas9 for In Vivo Gene Editing in Cystic Fibrosis." *Science Translational Medicine*, 14(632), eabc9998.
4. Doudna, J. A., & Charpentier, E. (2014). "The new frontier of genome engineering with CRISPR-Cas9." *Science*, 346(6213), 1258096.
5. Jinek, M., et al. (2012). "A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity." *Science*, 337(6096), 816-821.
6. Komor, A. C., et al. (2016). "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage." *Nature*, 533(7603), 420-424.
7. Rees, H. A., & Liu, D. R. (2018). "Base editing: precision chemistry on the genome and transcriptome of living cells." *Nature Reviews Genetics*, 19(12), 770-788.
8. Newby, G. A., & Liu, D. R. (2021). "In vivo somatic cell base editing and prime editing in mammals." *Nature Reviews Genetics*, 22(12), 789-800.
9. Anzalone, A. V., et al. (2019). "Search-and-replace genome editing without double- strand breaks or donor DNA." *Nature*, 576(7785), 149-157.
10. Gaudelli, N. M., et al. (2017). "Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage." *Nature*, 551(7681), 464-471.
11. Xu, L., et al. (2019). "CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia." *New England Journal of Medicine*, 381(13), 1240-1247.
12. Dever, D. P., et al. (2016). "CRISPR/Cas9 beta-globin gene targeting in human hematopoietic stem cells." *Nature*, 539(7629), 384-389.
13. Bak, R. O., et al. (2018). "Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR-Cas9 and AAV6." *eLife*, 7, e33022.
14. Li, C., et al. (2020). "Targeted correction of the β-globin gene in human hematopoietic stem cells for SCD treatment." *Science Translational Medicine*, 12(541), eaay0513.
15. Nelson, C. E., et al. (2016). "In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy." *Science*, 351(6271), 403-407.
16. Long, C., et al. (2016). "Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy." *Science*, 351(6271), 400-403.
17. Amoasii, L., et al. (2018). "Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy." *Science*, 362(6410), 86-91.
18. Cyranoski, D. (2019). "The CRISPR-baby scandal: what’s next for human gene- editing?" *Nature*, 566(7745), 440-442.
19. Ledford, H. (2020). "CRISPR treatment inserted directly into the body for first time."

*Nature*, 579(7798), 185.

1. Gyngell, C., et al. (2019). "The ethics of germline gene editing." *Journal of Medical Ethics*, 45(9), 545-548.
2. Barrangou, R., et al. (2007). "CRISPR provides acquired resistance against viruses in prokaryotes." *Science*, 315(5819), 1709-1712.
3. Sternberg, S. H., et al. (2014). "DNA interrogation by the CRISPR RNA-guided endonuclease Cas9." *Nature*, 507(7490), 62-67.
4. Nishimasu, H., et al. (2014). "Crystal structure of Cas9 in complex with guide RNA and target DNA." *Cell*, 156(5), 935-949.
5. Jiang, F., & Doudna, J. A. (2017). "CRISPR–Cas9 structures and mechanisms." *Annual Review of Biophysics*, 46, 505-529.
6. Hsu, P. D., et al. (2013). "DNA targeting specificity of RNA-guided Cas9 nucleases."

*Nature Biotechnology*, 31(9), 827-832.

1. Fu, Y., et al. (2014). "Improving CRISPR-Cas nuclease specificity using truncated guide RNAs." *Nature Biotechnology*, 32(3), 279-284.
2. Tsai, S. Q., et al. (2014). "Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing." *Nature Biotechnology*, 32(6), 569-576.
3. Slaymaker, I. M., et al. (2016). "Rationally engineered Cas9 nucleases with improved specificity." *Science*, 351(6268), 84-88.
4. Kleinstiver, B. P., et al. (2016). "High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects." *Nature*, 529(7587), 490-495.
5. Chen, J. S., et al. (2017). "CRISPR-Cas12a target binding unleashes single-stranded DNase activity." *Science*, 360(6387), 436-439.
6. East-Seletsky, A., et al. (2016). "Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection." *Nature*, 538(7624), 270-273.
7. Smargon, A. A., et al. (2017). "Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins." *Molecular Cell*, 65(4), 618-630.
8. Cox, D. B. T., et al. (2017). "RNA editing with CRISPR-Cas13." *Science*, 358(6366), 1019-1027.
9. Yan, W. X., et al. (2019). "Functionally diverse type V CRISPR-Cas systems." *Science*, 363(6422), 88-91.
10. Strecker, J., et al. (2019). "RNA-guided DNA insertion with CRISPR-associated transposases." *Science*, 365(6448), 48-53.
11. Klompe, S. E., et al. (2019). "Transposon-encoded CRISPR-Cas systems direct RNA- guided DNA integration." *Nature*, 571(7764), 219-225.
12. Abudayyeh, O. O., et al. (2017). "RNA targeting with CRISPR-Cas13." *Nature*, 550(7675), 280-284.
13. Kellner, M. J., et al. (2019). "SHERLOCK: nucleic acid detection with CRISPR nucleases." *Nature Protocols*, 14(10), 2986-3012.
14. Gootenberg, J. S., et al. (2017). "Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6." *Science*, 356(6336), 438-442.
15. Zhang, F., et al. (2021). "CRISPR-based technologies: challenges and opportunities."

*Cell*, 184(6), 1517-1532.